Tissue banking,bioinformatics,and electronic medical records: the front-end requirements for personalized medicine

Personalized medicine promises patient-tailored treatments that enhance patient care and decrease overall treatment costs by focusing on genetics and -omics data obtained from patient biospecimens and records to guide therapy choices that generate good clinical outcomes. the approach relies on diagnostic and prognostic use of novel biomarkers discovered through combinations of tissue banking,bioinformatics,and electronic medical records (emrs). the analytical power of bioinformatic platforms combined with patient clinical data from emrs can reveal potential biomarkers and clinical phenotypes that allow researchers to develop experimental strategies using selected patient biospecimens stored in tissue banks. for cancer,high-quality biospecimens collected at diagnosis,first relapse,and various treatment stages provide crucial resources for study designs. to enlarge biospecimen collections,patient education regarding the value of specimen donation is vital. one approach for increasing consent is to offer publically available illustrations and game-like engagements demonstrating how wider sample availability facilitates development of novel therapies. the critical value of tissue bank samples,bioinformatics,and emr in the early stages of the biomarker discovery process for personalized medicine is often overlooked. the data obtained also require cross-disciplinary collaborations to translate experimental results into clinical practice and diagnostic and prognostic use in personalized medicine. © 2013 k. stephen suh et al.